secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2021-10-07T23:59:59+00:00
Accession:  0001193125-21-294159
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC presents Phase 1b data on ORIC-101 in prostate cancer and preclinical data on ORIC-114
--------------------------------------------------------------------------------

- ORIC-101 (240 mg) + enzalutamide well tolerated at RP2D; adverse events mostly Grade 1-2, consistent with enzalutamide alone.
- No drug-drug interaction; plasma concentrations inhibited GR target; 76% of tumors had moderate-to-high GR expression.
- In patients lacking AR resistance markers (n=8), those with moderate/high GR (n=6) had prolonged time on treatment vs low GR (n=2).
- ORIC-114 showed superior brain penetration and tumor regressions in HER2+ breast cancer models; 90% CR in EGFR exon20 NSCLC xenograft.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312521294159/0001193125-21-294159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312521294159/d181647d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-294159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer